Clinical Trial: MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
Clinical Trial: MK2206 or Everolimus in Treating Patients With Refractory Kidney CancerSponsor and Collaborators
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Principal Investigator
Eric Jonasch, MD M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier
NCT01239342
